Asarina Pharma AB publ announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was SEK 16.012 million compared to SEK 17.938 million a year ago. Net loss was SEK 16.131 million compared to SEK 20.776 million a year ago. Basic loss per share from continuing operations was SEK 0.86 compared to SEK 1.11 a year ago. Diluted loss per share from continuing operations was SEK 0.81 compared to SEK 1.06 a year ago. For the half year, operating loss was SEK 22.787 million compared to SEK 38.959 million a year ago. Net loss was SEK 22.468 million compared to SEK 39.048 million a year ago. Basic loss per share from continuing operations was SEK 1.2 compared to SEK 2.09 a year ago. Diluted loss per share from continuing operations was SEK 1.14 compared to SEK 2 a year ago.